Kerry Wentworth - Net Worth and Insider Trading

Kerry Wentworth Net Worth

The estimated net worth of Kerry Wentworth is at least $1 Million dollars as of 2024-04-24. Kerry Wentworth is the Chief Regulatory Officer of Flexion Therapeutics Inc and owns about 146,362 shares of Flexion Therapeutics Inc (FLXN) stock worth over $1 Million. Kerry Wentworth is also the VP, Reg Affairs & Clinical Ops of Agenus Inc and owns about 21 shares of Agenus Inc (AGEN) stock worth over $156. Details can be seen in Kerry Wentworth's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kerry Wentworth has not made any transactions after 2021-07-19 and currently still holds the listed stock(s).

Transaction Summary of Kerry Wentworth

Kerry Wentworth Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kerry Wentworth owns 3 companies in total, including Flexion Therapeutics Inc (FLXN) , Agenus Inc (AGEN) , and Nuvation Bio Inc (NUVB) .

Click here to see the complete history of Kerry Wentworth’s form 4 insider trades.

Insider Ownership Summary of Kerry Wentworth

Ticker	Comapny	Transaction Date	Type of Owner
FLXN	Flexion Therapeutics Inc	2021-07-19	Chief Regulatory Officer
AGEN	Agenus Inc	2013-06-14	VP & Clinicial & Reg & & Quality
NUVB	Nuvation Bio Inc	2020-05-23	Chief Regulatory Officer

Kerry Wentworth Latest Holdings Summary

Kerry Wentworth currently owns a total of 2 stocks. Among these stocks, Kerry Wentworth owns 146,362 shares of Flexion Therapeutics Inc (FLXN) as of July 19, 2021, with a value of $1 Million and a weighting of 99.99%. Kerry Wentworth also owns 21 shares of Agenus Inc (AGEN) as of July 20, 2006, with a value of $156 and a weighting of 0.01%.

Latest Holdings of Kerry Wentworth

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
FLXN	Flexion Therapeutics Inc	2021-07-19	146,362	9.12	1,334,821
AGEN	Agenus Inc	2006-07-20	21	7.42	156

Holding Weightings of Kerry Wentworth

Kerry Wentworth Form 4 Trading Tracker

According to the SEC Form 4 filings, Kerry Wentworth has made a total of 2 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Flexion Therapeutics Inc is the sale of 3,944 shares on July 19, 2021, which brought Kerry Wentworth around $25,439.

According to the SEC Form 4 filings, Kerry Wentworth has made a total of 0 transactions in Agenus Inc (AGEN) over the past 5 years. The most-recent trade in Agenus Inc is the sale of 0 shares on July 20, 2006, which brought Kerry Wentworth around $0.

Insider Trading History of Kerry Wentworth

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kerry Wentworth Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kerry Wentworth Ownership Network

Ownership Network List of Kerry Wentworth

No Data

Ownership Network Relation of Kerry Wentworth

Kerry Wentworth Owned Company Details

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

Kerry Wentworth is the Chief Regulatory Officer of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Strategy Officer Christina Willwerth , General Counsel Mark S. Levine , and Chief Financial Officer David Arkowitz .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Flexion Therapeutics Inc Insider Transactions

No Available Data

What does Agenus Inc do?

Who are the key executives at Agenus Inc?

Kerry Wentworth is the VP & Clinicial & Reg & & Quality of Agenus Inc. Other key executives at Agenus Inc include Chairman & CEO Garo H Armen , Chief Medical Officer Steven J O'day , and VP Finance Christine M Klaskin .

Agenus Inc (AGEN) Insider Trades Summary

Over the past 18 months, Kerry Wentworth made no insider transaction in Agenus Inc (AGEN). Other recent insider transactions involving Agenus Inc (AGEN) include a net purchase of 500,000 shares made by Garo H Armen , and a net purchase of 25,000 shares made by Ulf Wiinberg .

In summary, during the past 3 months, insiders sold 0 shares of Agenus Inc (AGEN) in total and bought 25,000 shares, with a net purchase of 25,000 shares. During the past 18 months, 0 shares of Agenus Inc (AGEN) were sold and 26,250 shares were bought by its insiders, resulting in a net purchase of 26,250 shares.

Agenus Inc (AGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agenus Inc Insider Transactions

No Available Data

What does Nuvation Bio Inc do?

Who are the key executives at Nuvation Bio Inc?

Kerry Wentworth is the Chief Regulatory Officer of Nuvation Bio Inc. Other key executives at Nuvation Bio Inc include Chief Medical Officer Dongfang Liu , 10 percent owner Omega Fund V Gp, L.p. , and 10 percent owner Omega Fund Iv Gp, L.p. .

Nuvation Bio Inc (NUVB) Insider Trades Summary

Over the past 18 months, Kerry Wentworth made no insider transaction in Nuvation Bio Inc (NUVB). Other recent insider transactions involving Nuvation Bio Inc (NUVB) include a net purchase of 10,626,200 shares made by Oleg Nodelman , and a net purchase of 250,000 shares made by Kathryn E Falberg .

In summary, during the past 3 months, insiders sold 0 shares of Nuvation Bio Inc (NUVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Nuvation Bio Inc (NUVB) were sold and 10,876,200 shares were bought by its insiders, resulting in a net purchase of 10,876,200 shares.

Nuvation Bio Inc (NUVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvation Bio Inc Insider Transactions

No Available Data

Kerry Wentworth Mailing Address

Above is the net worth, insider trading, and ownership report for Kerry Wentworth. You might contact Kerry Wentworth via mailing address: Agenus Inc., 3 Forbes Road, Lexington Ma 02421.

Discussions on Kerry Wentworth

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.